Free database of papers and journals






Results 1 to 20 of 363 articles found
2002

Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families

European Urology Supplement (0.1 31), 1, 63.
2009

Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors

The Journal of Sexual Medicine (0.5 114), 6, 658-674.
2016

AB030. Evolution of phosphodiesterase type 5 inhibitors

Translational Andrology and Urology (1.2 28), 5, AB030-AB030.
2015

[Review] Phosphodiesterase type 5 inhibitors and kidney disease

International Urology and Nephrology (1.9 55), 47, 1521-1528.
2002

Type 5 phosphodiesterase expression in the human vagina

Urology (1.5 198), 60, 191-195.
2005

Phosphodiesterase type 5 inhibitors for erectile dysfunction

BJU International (3.5 149), 96, 257-280.
2007

Phosphodiesterase type 5 inhibitors and endothelial function

Current Sexual Health Reports (1.5 22), 4, 157-162.
2007

Nonurologic applications of phosphodiesterase type 5 inhibitors

Current Sexual Health Reports (1.5 22), 4, 64-70.
2008

Chronic dosing of phosphodiesterase type 5 inhibitors

Current Sexual Health Reports (1.5 22), 5, 65-69.
2007

Optimizing response to phosphodiesterase type 5 inhibitors

2007

Phosphodiesterase Type 5 Inhibitors: The Day After

European Urology (5.7 220★★), 51, 75-89.
2002

Editorial: Tachyphylaxis and Phosphodiesterase Type 5 Inhibitors

The Journal of Urology (0.4 312★★), 168, 207-207.
2002

Editorial: Tachyphylaxis and Phosphodiesterase Type 5 Inhibitors

The Journal of Urology (0.4 312★★), , 207.
2007

Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class

Urologic Clinics of North America (1.4 82), 34, 507-515.
2005

Why humans need type 5 phosphodiesterase inhibitors

2006

Type 5 Phosphodiesterase Inhibitors: Curing Erectile Dysfunction

European Urology (5.7 220★★), 49, 942-945.
2002

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction

Urology (1.5 198), 60, 4-11.
2004

Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis

EAU Update Series (13), 2, 56-63.
2017

Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors

Sexual Medicine Reviews (4.3 31), 5, 170-199.
2008

Combination therapy with phosphodiesterase type V inhibitors and testosterone

Current Sexual Health Reports (1.5 22), 5, 135-140.
Anatomy of Results
The left numbers are the publication year, and the number of citations (hyperlink to the full citation report of the paper)
paranthesis after the journal provides its impact factor.
paranthesis after the author indicates the number of publications and Author's Impact Factor
EXALY
Authors
Journals
Institutions